Emtricitabine, Tenofovir Disoproxil — Drug Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

4 Recruiting

10 Completed trials

6 Sponsors

19 Countries

Phase III

Phase II

Phase IV

Phase III: 8 Phase II: 3 Phase III/IV: 1 Phase IV: 2

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

Systemic lupus erythematosus 4 HIV infection 2 Sjogren's syndrome 2 Lupus nephritis 2 Rheumatoid arthritis 1 Systemic scleroderma 1

Sponsors using this IMP

Novartis Pharma AG 8 Inserm 2 Fondazione Penta Ets 1 Fundacion Seimc Gesida 1 Janssen - Cilag International 1 Radboud universitair medisch centrum Stichting 1

All trials

14 total

A randomized, two-period crossover study to demonstrate the comparability of pharmacokinetics of subcutaneous ianalumab between 2mL auto-inj… Recruiting

2023-508996-35-00 Phase II 7 countries Novartis Pharma AG
An open-label extension study to assess the efficacy and safety of ianalumab with or without study treatment withdrawal in adult participan… Recruiting

2024-515280-60-00 Phase III 5 countries Novartis Pharma AG
ANRS0392s ELDORADO : Phase III, open-label, randomized, multicenter trial EvaLuating the non-inferiority of DORAvirine versus DOlutegravir b… Recruiting

2023-508626-10-00 Phase III 1 country Inserm
Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS-… Recruiting

2023-505929-14-00 Phase III 11 countries Novartis Pharma AG
Impact of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis persistence and coverage in men who have sex with men in Fran… Ended

2024-510678-25-00 Phase III/IV 1 country Inserm
A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab … Ended

2024-511933-36-00 Phase II 10 countries Novartis Pharma AG
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’… Ended

2022-502966-26-01 Phase III 16 countries Novartis Pharma AG
A randomised non-inferiority trial with nested PK to assess DTG/3TC fixed dose formulations for the maintenance of virological suppression i… Ended

2024-520388-15-00 Phase III 1 country Fondazione Penta Ets
Phase 3 study to evaluate ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2) Ended

2023-508499-12-00 Phase III 4 countries Novartis Pharma AG
Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS… Ended

2023-508498-97-00 Phase III 7 countries Novartis Pharma AG
Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n… Ended

2023-508559-37-00 Phase III 9 countries Novartis Pharma AG
Phase IV comparative, randomized, open-label pilot study to evaluate the efficacy and safety of a rilpivirine-based antiretroviral treatment… Ended

2022-503110-23-00 Phase IV 1 country Fundacion Seimc Gesida
A Clinical Study to Investigate the Efficacy and Safety of JNJ-73763989 + Nucleos(t)ide Analog in Participants Co-infected with Hepatitis B … Ended

2023-506763-33-00 Phase II 3 countries Janssen - Cilag International
Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Ended

2024-515487-31-00 Phase IV 5 countries Stichting Radboud universitair medisch centrum

Showing 1–14 of 14 trials

← All drugs A–Z